QUINFAMIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H13Cl2NO4
Molecular Weight	354.185
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC(Cl)C(=O)N1CCCC2=C1C=CC(OC(=O)C3=CC=CO3)=C2

InChI

InChIKey=SBJGFIXQRZOVTO-UHFFFAOYSA-N

InChI=1S/C16H13Cl2NO4/c17-14(18)15(20)19-7-1-3-10-9-11(5-6-12(10)19)23-16(21)13-4-2-8-22-13/h2,4-6,8-9,14H,1,3,7H2

HIDE SMILES / InChI

Molecular Formula	C16H13Cl2NO4
Molecular Weight	354.185
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT02385058 | https://www.ncbi.nlm.nih.gov/pubmed/12139216 | http://www.scielo.cl/pdf/parasitol/v60n1-2/art09.pdf | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-77122005000100009 | https://www.ncbi.nlm.nih.gov/pubmed/6252530

Quinafimide is an investigational compound that has been used in trials for the treatment of Amoebiasis and Helminthiasis. This phase 4 trial combined Quinfamide with the approved compound Mebendazole. The details of the mechanism of action are not known, but the overall effect is intraluminal immobilization of the Entamoeba.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
cell motility 1 Target ID: GO:0048870 Sources: http://www.scielo.cl/pdf/parasitol/v60n1-2/art09.pdf \| http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-77122005000100009	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Amoebiasis 12 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12139216 https://www.drugbank.ca/drugs/DB12780	Secondary		Phase IV 63	Unknown Approved Use Unknown
Helminthiasis 39 Sources: https://www.drugbank.ca/drugs/DB12780 https://clinicaltrials.gov/ct2/show/NCT02385058	Secondary		Phase IV 63	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
100 mg single, oral Studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12139216/	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12139216/	Sources: https://pubmed.ncbi.nlm.nih.gov/12139216/
4.3 mg/kg single, oral Studied dose Dose: 4.3 mg/kg Route: oral Route: single Dose: 4.3 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/23315350/	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23315350/	Other AEs: Abdominal pain, Nausea... Other AEs: Abdominal pain (4%) Nausea (0.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/23315350/

AEs

AE	Significance	Dose	Population
Nausea	0.9%	4.3 mg/kg single, oral Studied dose Dose: 4.3 mg/kg Route: oral Route: single Dose: 4.3 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/23315350/	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23315350/
Abdominal pain	4%	4.3 mg/kg single, oral Studied dose Dose: 4.3 mg/kg Route: oral Route: single Dose: 4.3 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/23315350/	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23315350/

PubMed

Title	Date	PubMed
Antiamoebic chemoprophylaxis using quinfamide in children: a comparative study.	2002-04-20	12805964
Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children.	2002-03	12139216
A study with quinfamide in the treatment of chronic amebiasis in adults.	1983	6673830
The disposition of quinfamide in the rat.	1982-07	7138144
[Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study].	1980-04-01	7403767
1-(Dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol esters. New potent antiamebic agents.	1979-05	458814

Patents

Sample Use Guides

In Vivo Use Guide

In phase 4 clinical trial for the treatment of intestinal helminthiasis and amebiasis, Quinfamide (200 mg) was given orally in combination with oral Mebendazole (600 mg).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:16:47 GMT 2025` Edited by `admin` on `Mon Mar 31 18:16:47 GMT 2025`
Record UNII	O1ZB1046R1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

QUINFAMIDE

Official Name

English

WIN 40014

Preferred Name

English

QUINFAMIDE [MART.]

Common Name

English

Quinfamide [WHO-DD]

Common Name

English

WIN-40014

Code

English

QUINFAMIDE [USAN]

Common Name

English

2-Furoic acid ester with 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol

Systematic Name

English

quinfamide [INN]

Common Name

English

QUINFAMIDE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C277